The AKT3 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the AKT3 gene in the human 769-P clear cell renal cell carcinoma line. This product provides a heterogeneous pool of cells harboring loss-of-function mutations introduced at the AKT3 locus, enabling functional studies of AKT3-dependent signaling in a renal epithelial cancer context. The polyclonal format recapitulates the genetic diversity inherent to tumor cell populations and is well suited for pooled knockdown validation, bulk biochemical assays, and phenotypic screening without clonal selection bias.
The 769-P host cell line is an adherent epithelial line derived from a primary clear cell renal cell carcinoma, retaining wild-type VHL status. It serves as a well-characterized model for renal cell carcinoma research, exhibiting key features of kidney epithelial biology and tumor cell behavior. 769-P cells are routinely employed to investigate oncogenic signaling, metabolic reprogramming, and therapeutic vulnerabilities in renal cancer, providing a physiologically relevant background for targeted gene disruption studies.
AKT3 encodes a serine/threonine kinase that functions as a critical downstream effector of phosphoinositide 3-kinase (PI3K) signaling. It is activated by upstream regulators including EGF, IGF-1, and insulin through their respective receptors (EGFR, IGFR), leading to PI3K-mediated PIP3 production and recruitment of PDK1 and mTORC2, which phosphorylate and activate AKT3. Once active, AKT3 phosphorylates a broad array of downstream targets, including mTORC1 (via PRAS40 and TSC2), GSK3??, FOXO transcription factors, and the pro-apoptotic protein BAD, thereby promoting cell survival, proliferation, growth, and metabolism. AKT3 also interacts with chaperones (HSP90) and phosphatases (PP2A, PHLPP) that modulate its activity, and its signaling converges on key effectors such as S6K and eIF4E to drive protein synthesis and cell cycle progression.
In the 769-P renal cell carcinoma context, AKT3 knockout disrupts the PI3K-AKT-mTOR signaling axis, which is frequently hyperactivated in kidney cancers. Loss of AKT3 function is expected to attenuate phosphorylation of downstream substrates, potentially reducing cell viability, migratory capacity, and tumorigenic potential. Thus, this knockout model enables dissection of AKT3-specific contributions to renal tumorigenesis, independent of the closely related AKT1 and AKT2 isoforms, and permits investigation of compensatory signaling mechanisms that may arise upon pathway inhibition.
This polyclonal AKT3 knockout cell population is suited for a wide range of research applications, including mechanistic studies of PI3K pathway signaling, renal cell carcinoma modeling, and drug resistance investigations. Researchers can assess AKT3 disruption by western blotting for total AKT3 and phospho-AKT (Ser473/Thr308), RT-qPCR, or next-generation sequencing. Functional assays such as MTT or BrdU proliferation measurements, annexin V apoptosis detection, transwell migration/invasion assays, and phospho-signaling analysis (e.g., phospho-S6) are readily performed. The cells can be employed in colony formation and xenograft tumor growth assays to evaluate in vitro and in vivo tumorigenicity. This product offers a versatile tool for preclinical studies interrogating AKT3-dependent biology. For additional technical information, please contact Ascent Research.
